China approves Nuvectis drug ciprocopan for PNH treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. RTX
9. COF
10. GOOGL

Go back to China approves Nuvectis drug ciprocopan for PNH treatment

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

July 23, 2026 7:30 AM EDT

First global approval of a once-daily, orally administered, Complement Factor B inhibitor

Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNH

Ciprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under review

Ciprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring continuous life-long treatment

Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:... More